Transvaginal PVDF-mesh for cystocele repair: A cohort study by Barski, Dimitri et al.
lable at ScienceDirect
International Journal of Surgery 39 (2017) 249e254Contents lists avaiInternational Journal of Surgery
journal homepage: www.journal-surgery.netOriginal ResearchTransvaginal PVDF-mesh for cystocele repair: A cohort study
Dimitri Barski a, *, Christian Arndt a, Holger Gerullis b, Jin Yang c, Mihaly Boros d,
Thomas Otto a, Hans-Christian Kolberg e
a Department of Urology, Lukas Hospital, Neuss, Germany
b University Hospital for Urology, Klinikum Oldenburg, School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, Germany
c Department of Urology, Afﬁliated Hospital of Chengdu University, Chengdu, China
d Department of Experimental Surgery, University of Szeged, Hungary
e Department of Gynecology, Marienhospital Bottrop, Germanyh i g h l i g h t s PVDF- mesh is feasible for transvaginal application for cystocele repair.
 15% of patients presented any kind of complications and 8.8% needed a resurgery for SUI or POP during the follow-up.
 Improvement of quality of life was reported by 87.5% according the PGI-I.
 The preliminary results support the initiation of prospective trial and registry according to IDEAL.a r t i c l e i n f o
Article history:
Received 31 January 2017
Accepted 6 February 2017
Available online 10 February 2017
Keywords:
Anterior mesh
Alloplastic material
Biocompatibility
Vaginal wall prolapse
Cystocele
IDEAL* Corresponding author. Department of Urology,
ussenstr. 84, 41464 Neuss, Germany.
E-mail addresses: dbarski@lukasneuss.de (D. Ba
(C. Arndt), holger.gerullis@gmx.net (H. Gerullis),
boros.mihaly@med.u-szeged.hu (M. Boros), thomas_
hans-christian.kolberg@mhb-bottrop.de (H.-C. Kolber
http://dx.doi.org/10.1016/j.ijsu.2017.02.006
1743-9191/© 2017 IJS Publishing Group Ltd. Publisheda b s t r a c t
Introduction: Optimized biocompatibility of new materials is a major requirement for transvaginal
meshes for pelvic organ prolapse (POP) repair. Polyvinylidene ﬂuoride (PVDF) presented good charac-
teristics in prior animal experiments and clinical use in humans.
Methods: Between 01/2012 and 04/2016 37 women underwent transvaginal repair of symptomatic
prolapse of the anterior vaginal wall (cystocele) with PVDF-mesh in a single institution. A chart review
for recurrence, continence, peri- and early postoperative complications was performed. Referring prac-
titioners were interviewed by telephone and mail. Additionally patient reported outcome and satisfac-
tion were measured by Patient Global Improvement Inventory (PGI-I) scale.
Results: 34 women were eligible for a mean follow up of 19 months. The functional outcome improved
signiﬁcantly. One symptomatic vault prolapse (2.9%) and two reoperations for incontinence (5.9%)
occurred. Two mesh exposures (5.9%) occurred and were treated conservatively. No other severe com-
plications were registered. 87.5% of treated women felt very much better or much better and would
undergo the surgery again. A cohort study including development steps in accordance with the IDEAL
system is presented.
Conclusions: For the ﬁrst time we report on effectivity and safety of transvaginal application of PVDF-
mesh in real-life practice. A prospective long-term evaluation in a registry is justiﬁed.
© 2017 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
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tocele repair. Standardised trocar-guided meshes are applied in
prolapse surgery to reduce the recurrence of prolapse for decades.
Polypropylene (PP) meshes (Type 1, Amid-classiﬁcation) are the
most used [1]. New modiﬁcations with light-weight meshes,
coatings and partly resorbable materials have been proposed lately.
However, there are no standards and less evidence on relevant
biological and physical parameters of materials [2]. Due to insufﬁ-
cient medical product controls a lot of me-too meshes got approval
without the provision of studies ﬁrst. Food and Drugd.
Table 1
Baseline characteristics of 37 patients undergoing cystocele repair with PVDF-mesh.
Mean age, years ± SD (range) 66 (±11.5)
Parity
Median 2
Range 0e5
Cesarean deliveries, no. of patients (%) 1 (2.7)
Current smokers, no. of patients (%) 5 (13.5)
Body mass index, mean ± SD (range) 27 (±4.1)
Menopause, no. of patients (%) 33 (89.2)
Current use of hormone therapy, no. of patients (%) 11 (29.7)
Risk factors (diabetes mellitus, immunosuppression,
recurrent UTIs, PVR>100 ml), no. of patients (%)
14 (37.8)
Previous surgery for cystocele, no. of patients (%) 8 (21.6)
Prior pelvic surgery, no. of patients (%)
hysterectomy 13 (35.1)
sacrospinal ﬁxation 4 (10.8)
suburethral tape 1 (2.7)
Mean POP-Q grade, n ± SD (range) 3 ± 0.4 (2e4)
Grade II, n (%) 6 (16.2)
Grade III, n (%) 26 (70.3)
Grade IV, n (%) 5 (13.5)
Symptoms, no. of patients (%)
vaginal bulge 29 (78.4)
episodes of incontinence 13 (40.5)
pelvic pain 3 (8.1)
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due to the number of serious complications related to mesh
insertion. In January 2016 an FDA amendment was released, which
requires studies and clinical data before the application of trans-
vaginal meshes [3]. Postmarket-surveillance is required by the
European regulatory authorities. Alloplastic materials potentially
add to the complication proﬁle the aspects of trauma of insertion,
foreign body reaction to the implant in terms of inﬂammation,
infection and/or rejection, and the stability of the prosthesis over
time [4]. The rate of mesh-related complications after the implan-
tation of transvaginal mesh is about 15e25% and especially mesh
erosion up to 10% [5,6]. Other complications are obstruction, de
novo urge, chronic pain, dyspareunia and mesh erosion [7].
Biocompatibility is an important requirement for the perfect
ingrowth of the material. It is determined by the foreign body re-
action and inﬂammation and depends on different parameters like
type of polymer, pore size, material weight and others [8,9]. An
optimized surgical mesh permits the transmigration and local-
isation of immune cells and prevents adherence and inﬂammation
if directly exposed to visceral organs, vessels or nerves.
In reaction to FDA warnings, our international scientiﬁc collab-
oration group has recently developed and concluded preliminary
studies in order to investigate and improve biocompatibility of
surgical meshes [3,9e11]. Our entire innovative approach has been
conducted following the ﬁve stage IDEAL-D method of surgical
innovations (Idea, Development, Exploration, Assessment, and
Long-term study of Device) with the aim of comparability and
reproducibility at every single step of development [12,13]. Exper-
imental studies have been conducted ﬁrst and can be assigned to
preclinical stage 0 according to IDEAL-D [13]. For the ﬁrst time a
validated in vitro test system to compare the biocompatibility of
different meshes was developed [9]. Series of commonly used
meshes were incubated with patient tissue culture (muscle, con-
nective tissue and endothelium) and the adhesion and ingrowth of
tissue over time were assessed. The score system was then vali-
dated in a longterm animal [11]. Different meshes were inserted
intraperitoneally and as a fascia and muscle onlay in a sheep and
were explanted after hours, 3, 6, 12 and 24 mos. Complications
were evaluated and connective tissue and inﬂammatory reaction
were examined histologically. The study revealed comparable
ranking characteristics at every time point after explantation. The
in vivo performance of these meshes in a sheep model was pre-
dictable with a previously developed in vitro test system. The early
inﬂammatory reaction determined the outcome and mesh
biocompatibility [10].
After preliminary positive results on PVDF-mesh in vitro and in
a longterm animal study consecutive human application is pre-
sented in the current study according to the ﬁrst stage of IDEAL-D.
The aim of the study is to proof the efﬁcacy and safety of a new
mesh material in a real-life practice. Additional focus of the study
was on the Patient-Reported Outcome (PRO).
2. Methods
2.1. Patients
The study was carried out in accordance with the 1964 Helsinki
Declaration and its later amendments. An ethics vote has not been
applied for due to the retrospective design. 37 women were
retrospectively enrolled who underwent transvaginal anterior
PVDFmesh repair for POP between 2012 and 2016 in a single center
cohort study(Marienhospital Bottrop, Germany). All women gave
their signed informed consent for participation in this study. Study
methods and deﬁnitions were applied according to recommenda-
tions by the International Urogynecological Association (IUGA) andthe International Continence Society (ICS) [4,14]. Women in
reproductive age, planning of pregnancy were excluded for mesh
usage. Women with uterovaginal prolapse were recommended to
concomitant hysterectomy. The study group included parous
women with symptomatic grade II-IV anterior/apical prolapse
based on Pelvic Organ Prolapse Quantiﬁcation (POP-Q). All grade II
cystoceles were recurrent and symptomatic after previous surgery
for prolapse. Risk factors like recurrent or high grade cystocele,
obesity, chronic obstructive pulmonary disease, heavy physical la-
bour, previous pelvic ﬂoor surgeries and preference of the patients
were considered in cases of vaginal mesh insertion [5]. PVDF-mesh
was used due to beneﬁcial material characteristics found in previ-
ous studies [9e11]. From January 2012 through April 2016, patients
were screened by the participating surgeons for prolapse of the
anterior vaginal wall after referral by their Gynecologist. All pa-
tients experienced an unsuccessful conservative treatment prior to
operation. Exclusion criteria were previous cancer of any pelvic
organ, previous mesh implantation at the operation site, infection
at the operation site, chemo- or immunological therapy during the
last three months, pregnancy or wish for child. All patients selected
for the surgery underwent preoperative and postoperative clinical
examination and pelvic ﬂoor ultrasound by the referring Gynecol-
ogist. Table 1 presents the clinical characteristics of the study group.
Additionally the study was registered at German Clinical Trials
Register (DRKS), registration number DRKS00011264 and Research
Registry, registration number researchregistry2097.2.2. Surgical procedure
All surgeries were performed by one experienced Urogynecol-
ogist (HCK). The surgical procedures were standardised before
initiation of the study. All mesh procedures involved use of the
PVDF mesh (DynaMesh®-PR4, FEG Textiltechnik, Germany) (Fig. 1).
The material is a pre-cut non-absorbable monoﬁlament soft PVDF
mesh (6  4 cm) with four arms. This procedure may be performed
under spinal or general anesthesia. All patients had an intravenous
perioperative antibiotic prophylaxis. All patients were placed in the
lithotomy position with thighs ﬂexed at approximately 90. After
cleaning the entire surgical area with antiseptic, a suprapubic
catheter is placed. The anterior vaginal wall is cut and the cystocele
Fig. 1. PVDF-mesh (Dynamesh®, PR4), with permission of FEG Textiltechnik
(Germany).
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ivaginal fat tissue are exposed. At the superior part the dissection is
extended over the pelvic ﬂoor in order to expose the access to
obturator foramen on both sides. The preparation is done bluntly to
palpate spina ischiadica or arcus tendineus on both sides. Skin in-
cisions are done at the anteromedial margin of the foramen obur-
atorium and 2 cm posterior and 1 cm lateral of the site. Trocar is
inserted through foramen obturatorium, over the insertion of arcus
tendineus and is lead through colpotomy. The mesh arms are
introduced retrograde with trocar on both sides. After ﬁnding the
optimal tension- and wrinkle-free position the mesh arms are ﬁxed
apical with interrupted sutures of Vicryl. The colpotomy is closed
with continuous Vicryl suture (Fig. 2). Concomitant procedures
were performed if necessary, including hysterectomy in 20 pa-
tients, sacrospinal ﬁxation in 18 patients, sacrocolpopexy in 3 pa-
tients and posterior vaginal wall repair in 20 patients. During the
whole series we made several changes to our operative procedure
due to experience and mesh modiﬁcation:
1. From case 6 onwards a suprapubic tube was placed during the
surgery to enable a controlled postoperative bladder training for
the patients. All but one of previous cases needed a recathe-
terisation due to prolonged postoperative voiding difﬁculties.
Additionally a postoperative vaginal ultrasound examination
was performed in order to rule out a hematoma.Fig. 2. Cystocele repair with anterior vaginal wall insertion of a PVDF-mesh (Dyna-
mesh®, PR4), with permission of FEG Textiltechnik (Germany).2. After case 11 additional apical ﬁxation of the mesh arms with
interrupted sutures of Vicryl was done to prevent the moving or
shrinkage of the mesh.
3. After case 16 additional ﬁxation of the apical vaginal wall by
sacrospinal ﬁxation or sacrocolpexy was performed in cases of
apical prolapse in order to prevent recurrences in this
compartment.
4. From case 35 onward a new modiﬁed PVDF mesh (DynaMesh®-
PR4 visible, FEG Textiltechnik, Germany) was used. The new
mesh is MRI-visible, which enables a better postoperative con-
trol and has an additional apical part for a better ﬁxation.
However, MRI-studies are not presented in this study.2.3. Follow up
Postmenopausal patients received postoperative topical estro-
gen cream treatment. Patients stayed normally for one week in
hospital as standard care to train the bladder emptying. The
suprapubic catheter was removed before discharge after 5e7 days
and measured post-void residual urine volume (PVR) <100 ml. All
patients underwent clinical examination and pelvic ﬂoor ultra-
sound before discharge in the hospital. Medical records of women
included in the study were reviewed for preoperative characteris-
tics including risk factors (body mass index, smoking, number of
deliveries, diabetes etc.), postoperative complications according to
Clavien-Dindo classiﬁcation [15] and ICS/IUGA classiﬁcation [4].
The range of 15e25%mesh-related complications was deﬁned to be
met by the clinical outcome of this study [5,6]. At follow up the
patients were interviewed and examined by the referring Gyne-
cologists. The Gynecologists were interviewed by DB and CA about
the symptoms, complications and reoperations of the patients at
follow-up.
2.4. Patient reported outcome
The subjective measure of women's satisfaction was evaluated
by Patient Global Improvement Inventory (PGI-I) scale (range 1e7,
very much better to very much worse), which has been validated as
a measurement of global improvement after prolapse surgery
previously [16,17]. For the deﬁnition of complete success, we used a
simple yes/no question: “If you had to undergo surgery all over
again, would you still do it?” [17]. Additionally, treated women
were asked for postoperative complications and symptoms (Fig. 3).
2.5. Statistical analysis
The data were documented into Microsoft Excel software and
then transferred into an GraphPadPrism6.0 (Graphpad Software,
Inc.) data bank for statistical analysis. Descriptive statistic was used
for evaluation of complication rates and analysis of the question-
naire. Continuous data were checked for normality of distribution
before choosing between parametric and non parametric tests. The
results were presented as medians with range or means with
standard deviation (SD) in case of normal distribution. The t-test
was utilized for comparison of the complications between the
groups with or without concomitant operations and for the group
with surgical modiﬁcation by apical mesh ﬁxation. A p value below
0.05 was considered statistically signiﬁcant.
3. Results
Between January 2012 and April 2016 37 patients underwent
POP surgery with Dynamesh® PR4 for symptomatic cystocele in a
single institution. More than 80% presented grade 3 cystocele and
Fig. 3. Postoperative patient questionnaire with PGI-I scale [17].
D. Barski et al. / International Journal of Surgery 39 (2017) 249e25425221.6% underwent a previous surgery for cystocele. Vaginal bulge
symptoms were presented by 29 patients (78%) and 13 patients
(40.5%) suffered from episodes of incontinence at least once a week
(Table 1). Perioperative data is presented in Table 2. The mean
follow up was 19 months. Three patients were lost to follow up, as
they did not refer to their Gynecologist after the operation. In 86%
of patients concomitant operations (hysterectomy, sacrospinous
ﬁxation, sacrocolpopexy, posterior repair) were performed. NoTable 2
Surgical and perioperative characteristics.
General anesthesia, no. of patients (%) 35 (94.6)
Regional anesthesia, no. of patients (%) 2 (5.4)
Operation time, mean (min) 70 (±18.2)
Operation time (anterior mesh only), median (min) 40 (38e40)
Concomitant procedures, no. of patients (%)
hysterectomy 21 (56.7)
sacrospinal ﬁxation 18 (48.6)
abdominal sacrocolpopexy 3 (8.1)
posterior prolapse repair 20 (54)
Complications during surgery, no. of patients (%)
rectum lesion (Clavien-Dindo Grade I, ICS/IUGA: 5Aa/T1/S2) 1 (3.3)
blood loss in excess of 500 ml 0
Hospital stay, median (days) 7 (5e14)statistical signiﬁcance for the occurrence of complications was
detected for patients with concomitant operations. The efﬁcacy of
apical mesh ﬁxation was not signiﬁcant. Complications are pre-
sented in Table 3. Overall 15% of patients presented any kind of
complications and 8.8% needed a resurgery for SUI or POP during
the follow-up. Assuming the three lost to follow up patients to have
a bad outcome, overall 22% would suffer any kind of complications
and 16% would need a resurgery for SUI or POP during the follow-
up. In one case a rectal lesion 1 cm occurred during concomitant
posterior wall repair and was treated conservatively. No intra-
operative problems or complications associated with mesh inser-
tion were observed. There were three cases of vaginal wall
hematoma (8.8%, Clavien-Dindo I) during the hospital stay. Two
patients with transient postoperative voiding dysfunction and PVR
>100 ml were discharged with indwelling catheter (5.9%, Clavien-
Dindo II). There were two cases of mesh exposure (5.9%). In the
ﬁrst case there was a persisting postoperative mesh exposure due
to wound dehiscence and hematoma, a closure of the vaginal wall
under anesthesia was needed four weeks after the initial mesh
insertion (Clavien-Dindo III). Another case of vaginal mesh expo-
sure with temporary bleeding one year after initial surgery was
treated conservatively with topical estrogen. The symptoms were
relieved without a surgical intervention. Three patients suffered
from de novo incontinence (8.8%), in two cases a suburethral tape
was inserted over time (5.9%, Clavien-Dindo III). One patient
complained from prolapse and presented POP-Q grade III apical
prolapse recurrence 6 months after anterior mesh application and
concomitant sacrospinal ﬁxation. A repair with sacrocolopexy is
planned (2.9%, Clavien-Dindo III). One patient presented with
vaginal bleeding and pelvic pain and underwent hysterectomy two
years after the initial surgery. No other reoperations occurred
during the follow-up. No mesh resections or explantations were
necessary till the date of last follow up, which is September 2016.
From our collective 87.5% of treatedwomen felt verymuch better or
much better after the surgery and would undergo the surgery all
over again. However, at least two patients were not satisﬁed as
their symptoms did not change or got a little worse after the
operation, one woman suffered under recurrent prolapse and
another woman claimed persisting incontinence.
4. Discussion
Meshes are used for decades for the reinforcement of pelvic
ﬂoor tissue. However, meshes probably should not been used as
ﬁrst choice, but there are indications in case of higher risk of
recurrence [2,5]. The recurrence rates could be reduced signiﬁ-
cantly but for the price of an increased inﬂammatory and ﬁbrotic
tissue reaction to the implant. Current examinations show the
importance of acute inﬂammatory and immune responses for the
integration of mesh into the surrounding tissue [10,18]. The studies
aim to engineer a material which holds shape over time and re-
duces the inﬂammatory host reaction. Biomechanical characteris-
tics like effective porosity and material weight are crucial for the
mesh performance in host. According to the inﬂammatory reaction
and biomechanical characteristics new classiﬁcation of meshes has
been proposed recently by Klosterhalfen and Klinge [18].
Polyvinylidene ﬂuoride (PVDF) is a polymer with improved
textile and biological properties [19,20]. In comparison to other
materials like polyethylene-terephtalat (PET), PVDF is more resis-
tant to hydrolysis and degradation. Furthermore, ageing does not
increase the stiffness, evidently seen in polypropylene (PP). A
German group tested already 2002 PVDF mesh for abdominal wall
reconstruction in rats [19]. These results were supported and
standardised by our group in in vitro and large animal studies
showing good biocompatibility of PVDF [11]. In the preclinical
Table 3
Postoperative complications.
Postoperative complications Clavien-Dindo ICS/IUGA Classiﬁcation
Follow-up in mos, mean ± SD (range) 19 ± 8.5 (2e48)
Complications during hospital stay, no. of patients (%)
vaginal hematoma 3 (8.8) I 7A/S3/S4
catheter after hospital stay 2 (5.9) II 4B/T2
urinary tract infection 2 (5.9) II 4B/T2
Complications related to surgical procedure between hospital stay and follow up, no. of patients (%)
surgery for stress urinary incontinence 2 (5.9) III 4B/T2
surgery for prolapse recurrence 1 (2.9) III nd
mesh exposure 2 (5.9) I 2B/T1/S3
pelvic pain 1 (2.9) I 6B/T3/S5
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reduced inﬂammatory reaction and scarring at the implantation
site [9,11]. Several studies on PVDF mesh application for surgical
hernia repair are available. An Italian study proved Dynamesh®-
IPOM to be a safe and effective mesh for the laparoscopic repair of
incisional hernia in a small prospective trial [21]. Another study
analysed 181 patients from the National Danish Health Registry
after Dynamesh® application in laparoscopic ventral hernia repair.
They reported 6% risk of mesh-related reoperation and chronic pain
in 19%, however patient satisfaction was high after 34 months
follow-up [22]. To our knowledge there are only two German
studies reporting on small series of PVDF application for the
reconstruction of pelvic ﬂoor. Joukhadar and colleagues modiﬁed
laparoscopic bilateral sacropexy (MLBS) in 10 patients using a MRI-
visible PVDFmesh implant and reported favourable anatomical and
functional outcome after average follow-up of 7.4 months [23]. This
study can be assigned to stage 1 of IDEAL-system. Another single-
center randomized prospective clinical trial presented data on
laparoscopic bilateral ﬁxation of the vagina/cervix to the iliopecti-
neal ligaments via a PVDF-mesh in 44 patients versus 41 standard
laparoscopic sacropexies with PVDF-mesh [24]. The intermediate-
term follow-up (21.8 months for pectopexy and 19.5 months for
sacropexy) showed no mesh-related adverse events with high
overall satisfaction (>95%). This study can be assigned to stage 1 of
IDEAL-system, however we present large case series with detailed
information on surgical technique modiﬁcation and postoperative
follow-up.
Our study presents the ﬁrst transvaginal application of the
PVDF-mesh for cystocele repair. Most of the selected patients pre-
sented a symptomatic high grade cystocele (83.8%  grade III cys-
tocele, 78% with bulge symptoms) or recurrence after initial
anterior vaginal colporrhaphy (21.6%). All patients with grade II POP
were recurrent and had possible risk factors for reoperation, like
diabetes, obesity and multiple previous surgeries. A suprapubic
tube was placed during the operation and was removed after suc-
cessful bladder training during the hospital stay. Voiding dysfunc-
tion is a common transient complication of transvaginal anterior
mesh [5,6]. Altman et al. reported about transient bladder
emptying difﬁculties during the hospital stay in 8% of patients after
mesh repair [25]. A current German trial revealed that patients
cystocele repair using mesh are at increased risk of developing
postoperative voiding dysfunction, so that postoperative supra-
pubic bladder drainage is beneﬁcial [26]. Due to this management
only 2 patients needed the catheter over the time of hospital stay in
our series. The reason for voiding dysfunction were postoperative
hematoma, whichwas followed by pelvic ﬂoor ultrasound. Catheter
could be removed after several weeks.
Mesh-related complications were deﬁned by ICS/IUGA as
foreign body reaction to the implant in terms of inﬂammation,
infection and/or rejection, and the loss of effectivity over time [4].
The observed perioperative mesh-related complicationscorrespond to the data of current meta-analyses and studies [5,6].
The study was within the range of the reported mesh-related
complications. One case of apical prolapse recurrence can be
referred to a possible avulsion of sacrospinal ﬁxation and is not
related to the mesh. PVDF offers good mechanical stability over
19 mos follow up and less complications compared to the available
literature. Mesh erosion is reported to be about 10% after anterior
mesh application [6]. In our study there were two cases of mesh
exposure (5.9%), which could bemanaged successfully. The patients
with mesh exposure had several risk factors: current smoking
status, menopause and adiposity. However, the complication rates
were too low for multivariate analysis of risk factors [5]. No addi-
tional complications or intraoperative problems due to PVDF mesh
were observed.
Other studies reported previously on mesh modiﬁcations by
surface coating with collagen, titanium or absorbable polymers in
animal and in vitro studies [27e30]. However, the results are
inconsistent and study groups are small with few details on tech-
nical modiﬁcations. Some of these meshes have been now intro-
duced into the market since as they were thought to be associated
with lower complications. However, a standardised approach for
market approval of an innovation or new device according to
IDEAL-D system is needed. IDEAL demands structured and detailed
description of the procedure and innovation steps. Doing this, the
ﬁndings of studies are comparable for the researchers, bundle the
evidence and prevent the repetition of same experiments. Different
modiﬁcations of the surgical procedure over time are reported in
accordance with early development IDEAL stage.
The limitations of the presented study is the small patient
number and retrospective design, so that no statement on risk
factors and the efﬁcacy of surgical modiﬁcations for the outcome
was possible. The absolute number of longterm complications as
mesh exposure could be underestimated due to a follow up of less
than ﬁve years. There could be a selection bias due to three patients
lost to follow up. However, our study group was the ﬁrst one to
analyse the mesh modiﬁcation according to IDEAL-criteria of sur-
gical innovation [12]. Based on the preclinical results a monocentric
feasibility and development trial with method modiﬁcation is
presented. This study presents as well postmarket-surveillance
clinical data, as demanded by upcoming European medical device
regulations. A consecutive Urogynecological registry for implants is
currently under construction [31]. It is crucial that IDEAL-conform
studies will be supported in the future. Therefore research fun-
ders need to recognize the nature of surgical innovation to
encourage high-quality research approaches and improve the
outcome for our patients.
Overall, the anterior PVDF-insertion for cystocele repair is safe
and offers good functional results. The modiﬁcation is imple-
mented according to IDEAL-criteria of surgical innovations in a
real-life setting. In reaction to FDA-reports on mesh associated
problems, our international collaboration group present a unique
D. Barski et al. / International Journal of Surgery 39 (2017) 249e254254implementation of IDEAL-system for mesh graft development in
Urogynecology.
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